Cholangiocyte Biology and Cystic Fibrosis Liver Disease

Andrew P. Feranchak; Ronald J. Sokol

doi:10.1055/s-2001-19030

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2001; 21(4): 471-488
DOI: 10.1055/s-2001-19030

Cholangiocyte Biology and Cystic Fibrosis Liver Disease

Andrew P. Feranchak, Ronald J. Sokol

Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Children's Hospital and the University of Colorado Health Sciences Center, Denver, Colorado

Abstract

ABSTRACT

Cystic fibrosis (CF) is one of the most common inherited diseases in the white population. The disease results from mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR). How this gene defect leads to the clinical manifestations of the disease, however, is not entirely clear. CFTR functions as a Cl^- channel in the apical membrane of most secretory epithelia, including biliary epithelial cells, or cholangiocytes. In cholangiocytes, CFTR appears to be an important determinant of biliary secretion and bile flow. Additionally, recent evidence suggests that CFTR regulates other membrane transporters, channels, and proteins. Improving life expectancy has led to an increasing recognition of hepatobiliary complications from CF. The true prevalence of CF liver disease is unknown, but may affect up to 17-25% of CF patients. Clinical manifestations include hepatic steatosis, neonatal cholestasis, focal nodular cirrhosis, multilobular cirrhosis, and biliary tract complications. Why only a subset of CF patients develops severe liver disease and others with the same genotype do not is one of the many scientific curiosities of this disease. This review focuses on the function of CFTR in cholangiocytes with emphasis on ductular bile formation as well as the clinical consequences of abnormal CFTR, namely CF-associated liver disease. Data on the pathogenesis, prevalence, clinical course, and treatment of CF liver disease will be reviewed.

KEYWORD

Cl^- channel - cholestasis - bile - hepatocyte - secretion

Full Text

References

REFERENCES

1 Dodge J A, Morison S, Lewis P A. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child . 1997; 77 493-496
2 Kosorok M R, Wei W H, Farrell P M. The incidence of cystic fibrosis. Stat Med . 1996; 15 449-462
3 Gabriel S E, Brigman K N, Koller B H. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science . 1994; 266 107-109
4 Anderson J. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child . 2001; 56 344-399
5 Fitzsimmons S C. The changing epidemiology of cystic fibrosis. J Peds . 1993; 122 1-9
6 Cystic Fibrosis Foundation, Patient Registry 1999 Annual Data Report. Bethesda, MD, September 2000
7 DiSant'Agnese P, Darling R. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics . 1953; 12 549-563
8 Riordan J R, Rommens J M, Kerem B-S. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science . 1989; 245 1066-1073
9 Anderson M P, Gregory R J, Thompson S. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science . 1991; 253 202-205
10 Fuller C M, Benos D J. CFTR! Am J Physiol . 1992; 263 C267-C286
11 Cohn J A, Strong T A, Picciotto M A. Localization of CFTR in human bile duct epithelial cells. Gastroenterology . 1993; 105 1857-1864
12 McGill J, Gettys T W, Basavappa S. Secretin activates Cl channels in bile duct epithelial cells through a cAMP-dependent mechanism. Am J Physiol . 1994; 266 G731-G736
13 Nathanson M H, Boyer J L. Mechanisms and regulation of bile secretion. Hepatology . 1991; 14 551-566
14 Strazzabosco M, Mennone A, Boyer J L. Intracellular pH regulation in isolated rat bile duct epithelial cells. J Clin Invest . 1991; 87 1503-1512
15 Roberts S K, Kuntz S M, Gores G. Regulation of bicarbonate-dependent ductular bile secretion assessed by lumenal micropuncture of isolated rodent intrahepatic bile ducts. Proc Nat Acad Sci USA . 1993; 90 9080-9084
16 Fitz J G, Basavappa S, McGill J. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest . 1993; 91 319-328
17 Levine R A, Hall R C. Cyclic AMP in secretin choleresis. Evidence for a regulatory role in man and baboons but not in dogs. Gastroenterology . 1976; 70 537-544
18 Alvaro D, Cho W K, Mennone A. Effect of secretin on intracellular pH regulation in isolated rat bile duct epithelial cells. J Clin Invest . 1993; 92 1314-1325
19 Chenderovitch J. Secretory function of the rabbit common bile duct. Am J Physiol . 1972; 223 695-706
20 London C D, Diamond J M, Brooks F P. Electrical potential differences in the biliary tree. Biochim Biophys Acta . 1968; 150 509-517
21 Basavappa S, Middleton J P, Mangel A. Cl^- transport in human biliary cell lines. Gastroenterology . 1993; 104 1796-1805
22 Roberts S K, Yano M, Ueno Y. Cholangiocytes express the aquaporin CHIP and transport water via a channel-mediated mechanism. Proc Nat Acad Sci USA . 1994; 91 13009-13013
23 Marinelli R A, Pham L, Agre P. Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane. Evidence for secretin-induced vesicular translocation of aquaporin-1. J Biol Chem . 1997; 272 12984-12988
24 Marinelli R A, Pham L D, Tietz P S. Expression of aquaporin-4 water channels in rat cholangiocytes. Hepatology . 2000; 31 1313-1317
25 Gray M A, Pollard C E, Harris A. Anion selectivity and block of the small-conductance chloride channel on pancreatic duct cells. Am J Physiol . 1990; 259 C752-C761
26 Kunzelmann K, Gerlach L, Frobe U, Greger R. Bicarbonate permeability of epithelial chloride channels. Pfluegers Arch . 1991; 417 616-621
27 Ishiguro H, Steward M C, Wilson R W. Bicarbonate secretion in interlobular ducts from guinea-pig pancreas. J Physiol . 1996; 495(Part 1) 179-191
28 Soleimani M, Aronson P S. Ionic mechanisms of Na⁺/HCO₃ cotransport in rabbit renal basolateral membrane vesicles. J Biol Chem . 1989; 264 18302-18308
29 O'Reilly C M, Winpenny J P, Argent B E. Cystic fibrosis transmembrane conductance regulator currents in guinea pig pancreatic duct cells: inhibition by bicarbonate ions. Gastroenterology . 2000; 118 1187-1196
30 Choi J Y, Muallem D, Kiselyov K. Aberrant CFTR-dependent HCO₃ ^- transport in mutations associated with cystic fibrosis. Nature . 2001; 410 94-97
31 McGill J, Gettys T W, Basavappa S. GTP-binding proteins regulate high conductance anion channels in rat bile duct epithelial cells. J Membr Biol . 1993; 133 253-261
32 Schlenker T, Fitz J G. Calcium-activated chloride channels in a human biliary cell line: regulation by calcium/ calmodulin-dependent protein kinase. Am J Physiol . 1996; 271 G304-G310
33 Roman R M, Feranchak A P, Salter K D. Endogenous ATP regulates Cl^- secretion in cultured human and rat biliary epithelial cells. Am J Physiol . 1999; 276 G1391-G1400
34 Roman R M, Wang Y, Fitz J G. Regulation of cell volume in a human biliary cell line: calcium-dependent activation of K⁺ and Cl^- currents. Am J Physiol . 1996; 271 G239-G248
35 Clarke L L, Grubb B R, Yankaskas J. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in cftr(-/-) mice. Proc Nat Acad Sci USA . 1994; 91 479-483
36 Chinet T C, Fullton J M, Yankaskas J R. Mechanism of sodium hyperabsorption in cultured cystic fibrosis nasal epithelium: a patch-clamp study. Am J Physiol . 1994; 266(Part 1) C1061-C1068
37 Gabriel S, Clarke L L, Boucher R C. CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature . 1993; 363 263-266
38 Grubb B R, Vick R N, Boucher R C. Hyperabsorption of Na⁺ and raised Ca(2+)-mediated Cl^- secretion in nasal epithelia of CF mice. Am J Physiol . 1994; 266(Part 1) C1478-C1483
39 Egan M, Flotte T, Afione S. Defective regulation of outwardly rectifying Cl^- channels by protein kinase A corrected by insertion of CFTR. Nature . 1992; 358 581-584
40 Schwiebert E M, Egan M E, Hwang T-H. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell . 1995; 81 1063-1073
41 Hyde S C, Gill D R, Higgins C F. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature . 1993; 362 250-255
42 Gao L, Kim K J, Yankaskas J R. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol . 1999; 277(Part 1) L113-L118
43 Linsdell P, Hanrahan J W. Glutathione permeability of CFTR. Am J Physiol . 1998; 275 C323-C326
44 Kuver R, Ramesh N, Lau S. Constitutive mucin secretion linked to CFTR expression. Biochem Biophys Res Commun . 1994; 203 1457-1462
45 Schreiber R, Nitschke R, Greger R. The cystic fibrosis transmembrane conductance regulator activates aquaporin 3 in airway epithelial cells. J Biol Chem . 1999; 274 11811-11816
46 Schreiber R, Pavenstadt H, Greger R. Aquaporin 3 cloned from Xenopus laevis is regulated by the cystic fibrosis transmembrane conductance regulator. FEBS Lett . 2000; 475 291-295
47 Braunstein G M, Roman R M, Clancy J P. Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation. J Biol Chem . 2001; 276 6621-6630
48 Short D B, Trotter K W, Reczek D. An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem . 1998; 273 19797-19801
49 Fouassier L, Duan C Y, Feranchak A P. Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology . 2001; 33 166-176
50 McGill J, Basavappa S, Shimokura G H. Adenosine triphosphate activates ion permeabilities in biliary epithelial cells. Gastroenterology . 1994; 107 236-243
51 Alpini G, Glaser S, Robertson W. Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. Am J Physiol . 1997; 273(Part 1) G518-G529
52 Lazaridis K N, Pham L, Tietz P S. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest . 1997; 100 2714-2721
53 Hofmann A F. Bile acids. In: Arias IM, ed. The Liver: Biology and Pathobiology New York: Raven, 1994: 677-718
54 Yoon Y B, Hagey L R, Hofmann A F. Effect of side chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-Norursodeoxycholate in rodents. Gastroenterology . 1986; 90 837-852
55 Palmer R, Gurantz D, Hofmann A F. Hypercholeresis induced by norchenodeoxycholate in biliary fistula rodent. Am J Physiol . 1987; 252 G219-G228
56 Alpini G, Glaser S S, Ueno Y. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology . 1999; 116 179-186
57 Feranchak A P, Fitz J G, Roman R M. Volume-sensitive purinergic signaling in human hepatocytes. J Hepatol . 2000; 33 174-182
58 Roman R M, Wang Y, Lidofsky S D. Hepatocellular ATP-binding cassette protein expression enhances ATP release and autocrine regulation of cell volume. J Biol Chem . 1997; 272 21970-21976
59 Feranchak A P, Roman R M, Doctor R B. The lipid products of phosphoinositide 3-kinase contribute to regulation of cholangiocyte ATP and chloride transport. J Biol Chem . 1999; 274 30979-30986
60 Chari R S, Schutz S M, Haebig J A. Adenosine nucleotides in bile. Am J Physiol . 1996; 270 G246-G252
61 Knowles M R, Clarke L L, Boucher R C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med . 1991; 325 533-538
62 Schlenker T, Romac J MJ, Sharara A. Regulation of biliary secretion through apical purinergic receptors in cultured rat cholangiocytes. Am J Physiol . 1997; 273 G1108-G1117
63 Reisin I L, Prat A G, Abraham E H. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J Biol Chem . 1994; 269 20584-20591
64 Al-Awqati Q. Regulation of ion channels by ABC transporters that secrete ATP. Science . 1995; 269 805-806
65 Pasyk E A, Foskett J K. Cystic fibrosis transmembrane conductance regulator-associated ATP and adenosine 3′-phosphate 5′-phosphosulfate channels in endoplasmic reticulum and plasma membranes. J Biol Chem . 1997; 272 7746-7751
66 Parr C E, Sullivan D M, Paradiso A M. Cloning and expression of a human P2u nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc Nat Acad Sci USA . 1994; 91 3275-3279
67 Chan H C, Cheung W T, Leung P. Purinergic regulation of anion secretion by cystic fibrosis pancreatic duct cells. Am J Physiol . 1996; 271 C469-C477
68 Taylor A L, Schwiebert L M, Smith J J. Epithelial P2x purinergic receptor channel expression and function. J Clin Invest . 1999; 104 875-884
69 Bennett W D, Olivier K N, Zeman K L. Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med . 1996; 153(Part 1) 1796-1801
70 Sokol R J, Durie P R. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr . 1999; 28(Suppl 1) 1-13
71 Bhaskar K R, Turner B S, Grubman S A. Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (delta-f508) cystic fibrosis transmembrane conductance regulator. Hepatology . 1998; 27 7-14
72 Oppenheimer E H, Esterly J R. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr . 1975; 86 683-689
73 Peters R H, French P J, van Doorninck H J. CFTR expression and mucin secretion in cultured mouse gallbladder epithelial cells. Am J Physiol . 1996; 271(Part 1) G1074-G1083
74 Lindblad A, Hultcrantz R, Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology . 1992; 16 372-381
75 Malizia G, Brunt E M, Peters M G. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology . 1995; 108 145-156
76 Sokol R J. Fat-soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterol Clin North Am . 1994; 23 673-705
77 Sokol R J, Straka M S, Dahl R. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr Res . 2001; 49 519-531
78 Yerushalmi B, Dahl R, Devereaux M W. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology . 2001; 33 616-626
79 Pessayre D, Berson A, Fromenty B. Mitochondria in steatohepatitis. Semin Liver Dis . 2001; 21 57-69
80 Wilschanski M, Zielenski J, Markiewicz D. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr . 1995; 127 705-710
81 Koch C, Cuppens H, Rainisio M. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol . 2001; 31 1-12
82 Colombo C, Apostolo M G, Ferrari M. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr . 1994; 124 393-399
83 De Arce M, O'Brien S, Hegarty J. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet . 1992; 42 271-272
84 Duthie A, Doherty D G, Williams C. Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology . 1992; 15 660-664
85 Augarten A, Kerem B S, Yahav Y. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C → T mutation. Lancet . 1993; 342 25-26
86 Scott-Jupp R, Lama M, Tanner M S. Prevalence of liver disease in cystic fibrosis. Arch Dis Child . 1991; 66 698-701
87 Feigelson J, Anagnostopoulos C, Poquet M. Liver cirrhosis in cystic fibrosis-therapeutic implications and long term follow up. Arch Dis Child . 1993; 68 653-657
88 Maurage C, Lenaerts C, Weber A. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr . 1989; 9 17-20
89 Colombo C, Battezzati P M, Strazzabosco M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis . 1998; 18 227-235
90 Lindblad A, Strandvik B, Hjelte L. Incidence of liver disease in patients with cystic fibrosis and meconium ileus. J Pediatr . 1995; 126 155-156
91 Tanner M S, Taylor C J. Liver disease in cystic fibrosis. Arch Dis Child . 1995; 72 281-284
92 Williams S G, Westaby D, Tanner M S. Liver and biliary problems in cystic fibrosis. Br Med Bull . 1992; 48 877-892
93 Duthie A, Doherty D G, Donaldson P T. The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis. J Hepatol . 1995; 23 532-537
94 Rohlfs E M, Shaheen N J, Silverman L M. Is the hemochromatosis gene a modifier locus for cystic fibrosis?. Genet Test . 1998; 2 85-88
95 Nagel R A, Westaby D, Javaid A. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet . 1989; 2 1422-1425
96 Vawter G F, Shwachman H. Cystic fibrosis in adults: an autopsy study. Pathol Annu . 1979; 14(Part 2) 357-382
97 Sokol R J, Carroll N M, Narkewicz M R, Wagener J S, Accurso F J. Liver blood tests during the first decade of life in children with cystic fibrosis identified by newborn screening. Pediatr Pulm . 1994; 10 275
98 Kovesi T, Corey M, Tsui L-C. The association between liver disease and mutations of the cystic fibrosis gene. Pediatr Pulm . 1992; 8 244
99 Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology . 1999; 30 1151-1158
100 Gaskin K J, Waters D LM, Howman-Giles R. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med . 1988; 318 340-346
101 Debray D, Lykavieris P, Gauthier F. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol . 1999; 31 77-83
102 Craig J M. The pathological changes in the liver in cystic fibrosis of the pancreas. Am J Dis Child . 1957; 93 357-369
103 Vlaman H B, France N E, Wallis P G. Prolonged neonatal jaundice in cystic fibrosis. Arch Dis Child . 1971; 46 805-809
104 Shapira R, Hadzic N, Francavilla R. Retrospective review of cystic fibrosis presenting as infantile liver disease. Arch Dis Child . 1999; 81 125-128
105 Roy C C, Weber A M, Morin C L. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr . 1982; 1 469-478
106 Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child . 1996; 75 67-70
107 Colombo C, Crosignani A, Battezzati P M. Liver involvement in cystic fibrosis. J Hepatol . 1999; 31 946-954
108 Mack D R, Traystman M D, Colombo J L. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr . 1995; 127 881-887
109 di Sant'Agnese A P, Blanc W A. A distinctive type of biliary cirrhosis of the liver associated with cystic fibrosis of the pancreas. Pediatrics . 1956; 18 387-409
110 Feranchak A P, Sontag M K, Wagener J S. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr . 1999; 135 601-610
111 Willi U V, Reddish J M, Teele R L. Cystic fibrosis: its characteristic appearance on abdominal sonography. AJR . 1980; 134 1005-1010
112 Stern R C, Rothstein F C, Doershuk C F. Treatment and prognosis of symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr . 1986; 5 35-40
113 Angelico M, Gandin C, Canuzzi P. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology . 1991; 14 768-775
114 Colombo C, Bertolini E, Assaisso M L. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr . 1993; 82 562-565
115 Neglia J P, Fitzsimmons S C, Maisonneuve P. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med . 1995; 332 494-499
116 Potter C J, Fishbein M, Hammond S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?. J Pediatr Gastroenterol Nutr . 1997; 25 32-36
117 Williams S G, Evanson J E, Barrett N. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol . 1995; 22 513-521
118 Patriquin H, Lenaerts C, Smith L. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology . 1999; 211 229-232
119 Dogan A S, Conway J J, Lloyd-Still J D. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease. J Nucl Med . 1994; 35 432-435
120 O'Connor P J, Southern K W, Bowler I M. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology . 1996; 23 281-287
121 Colombo C, Castellani M R, Balistreri W F. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology . 1992; 15 677-684
122 Hubbard A M, Meyer J S, Mahboubi S. Diagnosis of liver disease in children: value of MR angiography. AJR . 1992; 159 617-621
123 Schoenau E, Boeswald W, Wanner R. High-molecular-mass (``biliary'') isoenzyme of alkaline phosphatase and the diagnosis of liver dysfunction in cystic fibrosis. Clin Chem . 1989; 35 1888-1890
124 Rattenbury J M, Taylor C J, Heath P K. Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis. J Clin Pathol . 1995; 48 771-774
125 Gerling B, Becker M, Staab D. Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med . 1997; 336 1611-1612
126 Leonardi S, Giambusso F, Sciuto C. Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis?. J Pediatr Gastroenterol Nutr . 1998; 27 603-605
127 Narkewicz M R, Smith D, Gregory C. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr . 1998; 26 49-55
128 Bianchetti M G, Kraemer R, Passweg J. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr . 1988; 7 688-693
129 Heuman D M. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology . 1993; 104 1865-1870
130 Erlinger S, Dumont M. Influence of UDCA on bile secretion. In: Paumgartner G, Stiehl A, Barbara L, et al., eds. Strategies for the Treatment of Hepatobiliary Disease Dordrecht, The Netherlands: Kluwer Academic, 1990: 35-42
131 Botla R, Spivey J R, Aguilar H. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther . 1995; 272 930-938
132 Shimokura G H, McGill J, Schlenker T. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl^- currents in a biliary cell line. Gastroenterology . 1995; 109 965-972
133 Calmus Y, Gane P, Rouger P. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology . 1990; 11 12-15
134 Colombo C, Battezzati P M, Podda M. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology . 1996; 23 1484-1490
135 Cotting J, Lentze M J, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut . 1990; 31 918-921
136 Colombo C, Setchell K D, Podda M. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr . 1990; 117 482-489
137 Galabert C, Montet J C, Lengrand D. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr . 1992; 121 138-141
138 van de Meeberg C P, Houwen R H, Sinaasappel M. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol . 1997; 32 369-373
139 Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology . 1998; 27 166-174
140 Lepage G, Paradis K, Lacaille F. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr . 1997; 130 52-58
141 Thomas P S, Bellamy M, Geddes D. Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid. Lancet . 1995; 346 1230-1231
142 Pierro A, Koletzko B, Carnielli V. Resting energy expenditure is increased in infants and children with extrahepatic biliary atresia. J Pediatr Surg . 1989; 24 534-538
143 Ramsey B W, Farrell P M, Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. Am J Clin Nutr . 1992; 55 108-116
144 Schuster S R, Shwachman H, Toyama W M. The management of portal hypertension in cystic fibrosis. J Pediatr Surg . 1977; 12 201-206
145 Berger K J, Schreiber R A, Tchervenkov J. Decompression of portal hypertension in a child with cystic fibrosis after transjugular intrahepatic portosystemic shunt placement. J Pediatr Gastroenterol Nutr . 1994; 19 322-325
146 Sanyal A J, Purdum III P P, Luketic V A. Bleeding gastroesophageal varices. Semin Liver Dis . 1993; 13 328-342
147 Stringer M D, Price J F, Mowat A P. Liver cirrhosis in cystic fibrosis. Arch Dis Child . 1993; 69 407
148 Noble-Jamieson G, Valente J, Barnes N D. Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child . 1994; 71 349-352
149 Couetil J P, Houssin D P, Soubrane O. Combined lung and liver transplantation in patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg . 1995; 110 1415-1422
150 Dennis C M, McNeil K D, Dunning J. Heart-lung-liver transplantation. J Heart Lung Transplant . 1996; 15 536-538
151 Palmer E, Wilhelm J M, Sherman F. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature . 1979; 277 148-150
152 Bedwell D M, Kaenjak A, Benos D J. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med . 1997; 3 1280-1284
153 Rubenstein R C, Egan M E, Zeitlin P L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest . 1997; 100 2457-2465
154 Rubenstein R C, Zeitlin P L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med . 1998; 157 484-490
155 Eidelman O, Guay-Broder C, van Galen J P. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA . 1992; 89 5562-5566
156 Illek B, Yankaskas J, Machen T E. cAMP and genistein stimulate HCO₃ ^- conductance through CFTR in human airway epithelia. Am J Physiol . 1997; 272 L752-L761
157 Illek B, Zhang L, Lewis N C. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol . 1999; 277(Part 1) C833-C839
158 Kelley T J, Al Nakkash L, Cotton C U. Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest . 1996; 98 513-520
159 Kelley T J, Thomas K, Milgram L J. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci USA . 1997; 94 2604-2608
160 Grubman S A, Fang S L, Mulberg A E. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary cell lines. Gastroenterology . 1995; 108 584-592
161 Yang Y, Raper S E, Cohn J A. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Nat Acad Sci USA . 1993; 90 4601-4605
162 Friedman S L. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol . 1997; 32 424-430
163 Friedman S L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem . 2000; 275 2247-2250
164 Britton R S, Bacon B R. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology . 1994; 41 343-348
165 Zhang M, Song G, Minuk G Y. Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Gastroenterology . 1996; 110 1150-1155